| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.22 | 4e-05 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.002 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.24 | 0.003 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.005 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.097 | 0.006 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.009 |